You are here: Home » News » Market » Text

XTL Biopharmaceuticals Has Acquired Proteologics Shares

放大字体  缩小字体 Release date:2016-11-30  Views:154
Core Tip: XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m). Th

XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m).

The company has purchased single share at an amount of NIS1.405($0.36).

The acquired shares represent all the shares of Teva in Proteologics and also represent nearly 31.35%of Proteologics issued and outstanding share capital.

Proteologics is a public traded company listed on the Tel Aviv Stock Exchange.

XTL focuses on late stage clinical development of drugs to treat multiple myeloma,schizophrenia and hepatitis C.

 
 
[ NewsSearch ]  [ Add to Favorites ]  [ Tell a friend ]  [ Print ]  [ Close the window ]

 
Total0bar [View All]  Related Comments

 
Recommended Graphic
RecommendNews
Click Ranking